ACC.17

Extended use of betrixaban beyond the usual period of parenteral prophylaxis with enoxaparin reduced venous thromboembolism (VTE) incidence among medically ill patients.

Risk reductions in composite outcomes of hospitalization for heart failure (HHF) and modes of cardiovascular (CV) death observed with empagliflozin were comparable to the reduction in the pre-specified composite of HHF or CV death in the EMPAG-REG OTUCOME trial

The efficacy of folic acid supplementation on the risk of stroke was greatest in the lowest quartile of platelet count among hypertensive adults.

Prophylactic IV amiodarone lowered the incidence of atrial fibrillation (AF) after esophagectomy but was associated with several adverse effects post-esophagectomy.

Study data found vitamin D to be an important risk factor for acute coronary syndrome (ACS) and severe coronary artery disease (CAD).

Among eligible patients with heart failure and reduced ejection fraction (HFrEF), use of spironolactone was associated with improved clinical outcomes.

The safety and efficacy of cangrelor was studied in a subgroup of patients taking unfractionated heparin for PCI in the modified intent-to-treat (mITT) population of the CHAMPION PHOENIX trial.

The data represents ~3,000 patients who had received the study drug in Phase 3 of GLORIA-AF with up to 2 years follow-up.

The network meta-analysis to compare the effects on CV outcomes among 3 major antidiabetic drug classes: DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors.

Clinicians who treat patients with heart disease should be aware of the increased risk of fractures and screen for bone disease in this patient population.